Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) has officially requested FDA expedited review for its lead drug candidate, AD04, aimed at treating Alcohol Use Disorder (AUD). The request is based on the unmet medical need for effective treatments, especially amid escalating AUD issues due to the COVID-19 pandemic. CEO William Stilley highlighted the ongoing Phase 3 clinical trial progress and the promising results from the Phase 2 trial, reinforcing AD04's potential. The drug also holds promise for additional addictive disorders, further emphasizing the importance of regulatory support.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO William Stilley will present on September 16 at 1:30 p.m. ET, with a live webcast available. Adial focuses on addiction treatments, with its lead drug AD04 targeting Alcohol Use Disorder (AUD) via a genetic approach. A Phase 2b trial showed significant effectiveness in reducing drinking behaviors without serious safety concerns. AD04 may also help treat other addictions such as opioids and gambling.
Adial Pharmaceuticals (NASDAQ:ADIL, ADILW) announced its participation in the LD Micro 500 Virtual Investor Conference from September 1-4, 2020. The CEO, William Stilley, will present on September 2 at 3:20 p.m. ET, with a live webcast available. The conference showcases key players in the small and micro-cap sector, featuring one-on-one meetings via video calls. Adial is focused on developing treatments for addictions, particularly its lead product AD04, currently in Phase 3 trials for Alcohol Use Disorder. For more information, visit Adial's website.